Table 3 Performance of AKI markers for predicting persistent AKI
Parameters | Sample (n) | AUROC [95% CI] | Cutoff value | Younden index | Sensitivity [95% CI] | Specificity [95% CI] | PPV [95% CI] | NPV [95% CI] | Brier score# |
|---|---|---|---|---|---|---|---|---|---|
[TIMP-2]*[IGFBP7] at 0 h ([ng/ml]2/1000) | 184 | 0.67 [0.59–0.73] | > 1.03 | 0.33 | 74 [63–83] | 59 [48–68] | 59 [53–66] | 73 [65–80] | 0.23 |
[TIMP-2]*[IGFBP7] at 6 h ([ng/ml]2/1000) | 172 | 0.73 [0.66–0.80] | > 2.3 | 0.36 | 48 [36–60] | 88 [79–93] | 75 [63–84] | 68 [63–73] | 0.21 |
[TIMP-2]*[IGFBP7] at 12 h ([ng/ml]2/1000) | 165 | 0.70 [0.63–0.77] | > 1.1 | 0.39 | 56 [44–68] | 83 [74–90] | 71 [60–80] | 72 [65–77] | 0.21 |
[TIMP-2]*[IGFBP7] at 24 h ([ng/ml]2/1000) | 156 | 0.68 [0.60–0.75] | > 0.43 | 0.27 | 67 [54–78] | 60 [49–70] | 54 [46–61] | 72 [64–79] | 0.21 |
∆[TIMP-2]*[IGFBP7] 0 to 6 h (%) | 172 | 0.59 [0.51–0.67] | > − 55.6 | 0.22 | 78 [67–87] | 44 [34–54] | 51 [42–61] | 72 [59–83] | 0.24 |
∆[TIMP-2]*[IGFBP7] 0 to 12 h (%) | 165 | 0.57 [0.49–0.65] | > − 67.1 | 0.16 | 74 [62–84] | 42 [32–53] | 49 [39–58] | 68 [55–80] | 0.24 |
Baseline urine output (ml/kg/h) | 184 | 0.78 [0.71–0.83] | < 0.40 | 0.50 | 62 [51–72] | 88 [80–94] | 81 [71–88] | 73 [67–78] | 0.21 |
Urine output 6 to 12 h (ml/kg/h) | 184 | 0.74 [0.67–0.80] | < 0.46 | 0.46 | 58 [47–69] | 88 [80–93] | 80 [69–87] | 72 [66–77] | 0.21 |
Urine output 12 to 24 h (ml/kg/h) | 184 | 0.75 [0.68–.081] | < 0.47 | 0.42 | 54 [43–65] | 88 [80–94] | 79 [66–70] | 61 [61–78] | 0.22 |
SCr concentration at baseline (μmol/l) | 184 | 0.63 [0.56–0.70] | > 179 | 0.29 | 52 [41–63] | 77 [67–85] | 66 [53–77] | 65 [56–74] | 0.24 |
SCr concentration at 24 h* (μmol/l) | 160 | 0.84 [0.77–0.89] | > 139 | 0.60 | 79 [67–88] | 81 [71–88] | 75 [63–84] | 84 [75–91] | 0.16 |
Kinetic eGFR* (ml/min per 1.73 m2) | 160 | 0.86 [0.80–0.91] | < 51 | 0.59 | 79 [67–88] | 80 [71–88] | 74 [63–84] | 84 [75–91] | 0.15 |